358 related articles for article (PubMed ID: 20855046)
21. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Chou TL; Chia S; Shang CY; Gau SS
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
[TBL] [Abstract][Full Text] [Related]
22. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.
Arnsten AF; Pliszka SR
Pharmacol Biochem Behav; 2011 Aug; 99(2):211-6. PubMed ID: 21295057
[TBL] [Abstract][Full Text] [Related]
23. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Psychol Med; 2014 Feb; 44(3):633-46. PubMed ID: 23597077
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
25. Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.
Baskin BM; Nic Dhonnchadha BÁ; Dwoskin LP; Kantak KM
Psychopharmacology (Berl); 2017 Oct; 234(19):2897-2909. PubMed ID: 28730282
[TBL] [Abstract][Full Text] [Related]
26. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong J; Dilla T; Arellano J
BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
[TBL] [Abstract][Full Text] [Related]
27. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
[TBL] [Abstract][Full Text] [Related]
28. The neurobiology of attention-deficit/hyperactivity disorder.
Chamberlain SR; Robbins TW; Sahakian BJ
Biol Psychiatry; 2007 Jun; 61(12):1317-9. PubMed ID: 17556026
[No Abstract] [Full Text] [Related]
29. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
30. A Dopamine D
Yang Y; Lewis MM; Kong L; Mailman RB
J Pharmacol Exp Ther; 2022 Aug; 382(2):88-99. PubMed ID: 35661631
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
32. Differential sensitivity to psychostimulants across prefrontal cognitive tasks: differential involvement of noradrenergic α₁ - and α₂-receptors.
Berridge CW; Shumsky JS; Andrzejewski ME; McGaughy JA; Spencer RC; Devilbiss DM; Waterhouse BD
Biol Psychiatry; 2012 Mar; 71(5):467-73. PubMed ID: 21890109
[TBL] [Abstract][Full Text] [Related]
33. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
34. Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism.
Hara Y; Ago Y; Taruta A; Katashiba K; Hasebe S; Takano E; Onaka Y; Hashimoto H; Matsuda T; Takuma K
Autism Res; 2016 Sep; 9(9):926-39. PubMed ID: 26714434
[TBL] [Abstract][Full Text] [Related]
35. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
36. Methylphenidate and venlafaxine attenuate locomotion in spontaneously hypertensive rats, an animal model of attention-deficit/hyperactivity disorder, through α2-adrenoceptor activation.
Umehara M; Ago Y; Kawanai T; Fujita K; Hiramatsu N; Takuma K; Matsuda T
Behav Pharmacol; 2013 Aug; 24(4):328-31. PubMed ID: 23751518
[TBL] [Abstract][Full Text] [Related]
37. Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors.
Andrews GD; Lavin A
Neuropsychopharmacology; 2006 Mar; 31(3):594-601. PubMed ID: 15999146
[TBL] [Abstract][Full Text] [Related]
38. Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
Heinrich H; Studer P; Moll GH; Kratz O
JAMA Psychiatry; 2013 May; 70(5):545. PubMed ID: 23636880
[No Abstract] [Full Text] [Related]
39. [Towards an understanding of the molecular mechanisms underlying the pharmacological treatments of attention deficit hyperactivity disorder].
Castellanos FX; Acosta MT
Rev Neurol; 2011 Mar; 52 Suppl 1():S155-60. PubMed ID: 21365598
[TBL] [Abstract][Full Text] [Related]
40. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Niederhofer H
Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
